Skip to main content

Phase 1a/1b Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, CTRM-505 and DTRM-555, in Patients with Chronic Lymphocytic Leukemia or Other B-Cell Lymphomas

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Zhejiang DTRM Biopharma Co.Ltd.

Start Date

February 28, 2018

End Date

April 30, 2023
 

Administered By

Duke Cancer Institute

Awarded By

Zhejiang DTRM Biopharma Co.Ltd.

Start Date

February 28, 2018

End Date

April 30, 2023